A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
- Sylvia Adams
- , Megan Othus
- , Sandip Pravin Patel
- , Kathy D. Miller
- , Rashmi Chugh
- , Scott M. Schuetze
- , Mary D. Chamberlin
- , Barbara J. Haley
- , Anna Maria V. Storniolo
- , Mridula P. Reddy
- , Scott A. Anderson
- , Collin T. Zimmerman
- , Anne P. O’Dea
- , Hamid R. Mirshahidi
- , Jordi Rodon Ahnert
- , Frank J. Brescia
- , Olwen Hahn
- , Jane M. Raymond
- , David D. Biggs
- , Roisin M. Connolly
- New York University
- SWOG Statistics and Data Management Center
- Fred Hutchinson Cancer Research Center
- University of California at San Diego
- Indiana University-Purdue University Indianapolis
- University of Michigan, Ann Arbor
- Norris Cotton Cancer Center
- University of Texas Southwestern Medical Center
- Dayton Physicians LLC-
- Goldschmidt Cancer Center
- Kaiser Permanente
- University of Kansas Hospital
- Loma Linda University Health
- University of Texas MD Anderson Cancer Center
- Medical University of South Carolina
- The University of Chicago
- Alle-gheny General Hospital
- Centura Health
- Johns Hopkins University
- National Institutes of Health
- Dana-Farber Cancer Institute
- Oregon Health and Science University
- Northwestern University
Research output: Contribution to journal › Article › peer-review